Clinical trial Recruiting at 1 site Observational Ages 18 to 45 Women only

Investigating cardiovascular markers in women with PCOS during glucose testing

Official title: The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome

Run by Attikon Hospital · NCT06889454 · Data updated 2026-11-12

This study is testing how glucose testing affects heart health markers in women with PCOS and whether different treatments can improve those markers over six months.

More Metabolic Syndrome trials

Quick facts

Study typeObservational
Ages18 Years to 45 Years
SexWomen only
Enrollment120 (estimated)
SponsorAttikon Hospital
Academic / other
Locations1 site (Chaïdári)
StatusRecruiting
StartedFebruary 1, 2024
Main results expectedFebruary 1, 2025
Study endsFebruary 1, 2026
Registry record updatedNovember 19, 2025
Trial IDNCT06889454 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women over 16 years old with a diagnosis of PCOS who have not received treatment for the condition in the past six months.

Probably not a fit

Patients with conditions mimicking PCOS, such as thyroid disease or type 2 diabetes, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore cardiovascular and endothelial function markers in women diagnosed with PCOS during an oral glucose tolerance test (OGTT). Participants will undergo measurements of glucose, insulin, and various cardiovascular parameters at specific intervals during the OGTT. Additionally, the study will assess the impact of treatment interventions such as GLP-1 receptor agonists, oral contraceptives, and lifestyle modifications on these markers over a six-month period. The primary endpoints focus on changes in global longitudinal strain, pulse wave velocity, and perfused boundary region during the OGTT and after treatment.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of cardiovascular risks in women with PCOS.

How similar studies have gone: While there have been studies on cardiovascular risks in PCOS, this specific approach focusing on acute changes during OGTT is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age \> 16 years old
2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:

   * Clinical or biochemical hyperandrogenism
   * Anovulation or oligo-ovulation
   * Polycystic ovarian morphology (PCOM)
3. Absence of treatment for PCOS the last six months
4. Patients who have the ability to understand and sign the consent form.

Exclusion Criteria:

1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \[17-OHP\]), Cushing syndrome, acromegaly
2. Treatment with contraceptive or metformin
3. Type 2 diabetes mellitus
4. Treatment for diabetes
5. Pregnancy
6. Lactation
7. Malignancy

Where it's running

  • Attikon University General Hospital
    Chaïdári, Greece
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.